611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO, CA
End of Material Contract
Earnings Release
Investor Presentation
Secures Up to $50 Million in Growth Capital from Avenue Capital
Keli Walbert Appointed as Director of Spruce Biosciences, Inc.
Director Resignation - Tiba Aynechi Steps Down from Board
Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Director Departure - Bali Muralidhar Resigns from Board of Directors
FY 2025
Q3
Q2
Q1
FY 2024
Notice of Late Filing for Annual Report
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Amended Schedule 13G - Ownership Report